| External factors: | C2-ceramide |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Lung cancer |
| Experiment: | Cell cycle analysis//SA-β-gal activity assay |
| Description: | C2-ceramide accelerated PTX-induced G2-phase arrest of H1299 cells,as indicated by the portion of G2 population increased from 27.9% (PTX-treated) to 35.4% (20CT, PTX/C2-ceramide-treated);The percentage of senescent cells was significantly increased when PTX and C2-ceramide were co-administered to the cells,indicating C2-ceramide helped sensitize PTX-induced premature senescence both in a dose-dependent manner and time-dependent manner. |
| Regulatory pathway: | MAPK |
| R-EF-Pathway: | Activation |
| Official symbol(s): | MAPK |
| Pathway experiment: | Western blot |
| Pathway description: | To examine whether C2-ceramide sensitized cells to premature senescence through MAPK signaling pathways, protein levels of major stress-MAPKs (JNK and p38) and anti-apoptotic protein Bcl-2 were analyzed by western blotting. C2-ceramide treatment induced activation of p38 in a dose-responsive manner; Additionally, the activiation of JNKwas minor decreased with C2-ceramide treatment alone. |
Annotation: